Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Alamar Biosciences, Inc.NASDAQ: ALMR
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables of -$967K in Q2 FY2026
Q2 FY2026 accounts receivables was -$967K.
Context
- Accounts receivables amounted to 7.4% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (5.5M) USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.5M) | — |
Accounts Receivables vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 accounts receivables of $5.5M is the 4th largest of the 9 companies compared; the peer median is $890.5K.
- Accounts receivables amounts to 7.4% of revenue for ALMR, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $68.62M | +351.8% | — | 11.1% | |
| LTM Sep 2026 | $45.43M | -188.5% | -22.7% | 3.7% | |
| LTM Sep 2026 | $13.8M | -38.3% | +47.3% | 3.0% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $5.5M | — | — | 7.4% |
| LTM Mar 2026 | $2.3M | +273.6% | — | 1.4% | |
| LTM Mar 2026 | $1.1M | -82.4% | — | 1.3% | |
| LTM Mar 2026 | $1.1M | +37.9% | — | 7.3% | |
| LTM Mar 2026 | $683K | +174.7% | — | 36.9% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ALMR) | $890.5K | +37.9% | +12.3% | 3.7% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (29.82M) |
| Depreciation & Amortization | 3.86M |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.87M |
| Change in Working Capital | (32.57M) |
| Accounts Receivables | (5.5M) |
| Inventory | (23.78M) |
| Accounts Payables | (572K) |
| Other Working Capital | (2.72M) |
| Other Non-Cash Items | 2.05M |
| Operating Cash Flow | (53.61M) |
| Capital Expenditures | (6.38M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (4.94M) |
| Sales of Investments | 57.5M |
| Other Investing Activities | (1.01M) |
| Investing Cash Flow | 46.18M |
| Debt Repayment | 10M |
| Common Stock Issued | 1.49M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (657K) |
| Financing Cash Flow | 10.84M |
| Effect of Forex Changes | (172K) |
| Net Change in Cash | 3.23M |
| Free Cash Flow | (59.99M) |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.